ArticleNature communications2025
Systematic biotechnological production of isoprenoid analogs with bespoke carbon skeletons.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in Functional Genomics and Biotechnology for Enhancing Therapeutic Potential of Medicinal Plants.International journal of molecular sciences · 2026Review
- Tuning aromatic cage occupancy in prenyltransferases enables selective and efficient production of rare c-prenylated flavonoids.Nature communications · 2026Article
- Expanding the Terpene Universe: Synthetic Biology and Non-Natural Chemistry in Engineered Microorganisms.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Natural products are widely used as pharmaceuticals, flavors, fragrances, and cosmetic ingredients. Synthesizing and evaluating analogs of natural products can considerably expand their applications. However, the chemical synthesis of analogs of natural products is severely hampered by their highly complex structures. This is particularly evident in isoprenoids, the largest class of natural products. Here, we develop a yeast cell-based biocatalytic method that enables the systematic biotechnological production of analogs of different classes of isoprenoids (including monoterpenoids, sesquiterpenoids, triterpenoids, and cannabinoids) with additional carbons in their skeletons. We demonstrate the applicability of this approach through two proof-of-concept studies: the biosynthesis of the highly valued aroma ingredient ethyllinalool, and the production of cannabinoid analogs with improved cannabinoid receptor agonism. This method is simple, readily adaptable to any cell factory, and enables the tailored expansion of the isoprenoid chemical space to identify molecules with improved properties and the biotechnological production of valuable compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.